Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Autoimmune Diseases of the Nervous System 1Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1

Interventions

Cytarabine 7Cyclophosphamide 7Dexamethasone 6venetoclax 4blinatumomab 4Methotrexate 4Inotuzumab Ozogamicin 4pegaspargase 3merphos 3Vincristine 3Specimen Handling 3prednylidene 2dexamethasone acetate 2dexamethasone 21-phosphate 2deltacortene 2calaspargase pegol 2azathiopurine 2auricularum 2Prednisone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Calcium Dobesilate 2Biopsy 2Asparaginase 2trametinib 1ruxolitinib 1olverembatinib 1ofatumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × ofatumumab × Clear all
NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡